Literature DB >> 8551607

Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.

E J Arts1, J P Marois, Z Gu, S F Le Grice, M A Wainberg.   

Abstract

We have compared the effects of nucleoside analogs in quiescent and phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC) exposed to human immunodeficiency virus type 1 (HIV-1) with those of their triphosphorylated derivatives in cell-free HIV-1 reverse transcription assays. We observed a substantial decrease in synthesis of early minus-strand proviral DNA products in HIV-1-infected, quiescent PBMC exposed to each of 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddI), and 2',3'-dideoxy-3'-thiacytidine (3TC), in comparison with nontreated, infected controls. In contrast, no such diminution was observed when PHA-stimulated, HIV-1-infected PBMC were treated with the same drugs. This result was attributed to previously reported findings that PHA-stimulated PBMC possessed larger deoxynucleoside triphosphate (dNTP) pools than quiescent cells did. To further investigate this subject, a cell-free HIV-1 reverse transcription reaction involving HIV-1 RNA genomic template, recombinant purified HIV-1 reverse transcriptase, all four dNTPs and either tRNA3Lys or a deoxyoligonucleotide as primer was used to monitor chain termi-nation mediated by 2',3'-dideoxynucleoside triphosphates (ddNTPs) during synthesis of minus-strand strong-stop DNA. Augmented chain termination was observed with decreasing concentrations of both ddNTP and dNTP when the ratio of dNTP to ddNTP was fixed. We also found that both the number and strength of reverse transcription pause sites were increased at low concentrations of dNTPs and when a deoxyoligonucleotide primer was used in place of the cognate primer, tRNA3Lys. Preferential incorporation of ddATP was observed dur-ing reverse transcription opposite a distinct pause site in a short synthetic RNA template. These results con-firm the notion that the antiviral activities of ddNTP are dependent on both cellular dNTP pools and the state of cellular activation. Pausing of HIV-1 reverse transcriptase during reverse transcription, altered by dNTP concentrations, may be a mechanism that controls the position and extent of incorporation of nucleoside analogs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8551607      PMCID: PMC189871     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Inhibition of human immunodeficiency virus 1 reverse transcriptase by 3'-azidothymidine triphosphate.

Authors:  O Heidenreich; M Kruhøffer; F Grosse; F Eckstein
Journal:  Eur J Biochem       Date:  1990-09-24

2.  Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases.

Authors:  P Huang; D Farquhar; W Plunkett
Journal:  J Biol Chem       Date:  1990-07-15       Impact factor: 5.157

3.  Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients.

Authors:  M Rozencweig; C McLaren; M Beltangady; J Ritter; R Canetta; L Schacter; S Kelley; C Nicaise; L Smaldone; L Dunkle
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

4.  Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate.

Authors:  J E Reardon; W H Miller
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

5.  BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.

Authors:  D Richman; A S Rosenthal; M Skoog; R J Eckner; T C Chou; J P Sabo; V J Merluzzi
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

6.  Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5'-triphosphates of carbovir, 3'-azido-3'-deoxythymidine, 2',3'-dideoxyguanosine and 3'-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs.

Authors:  W B Parker; E L White; S C Shaddix; L J Ross; R W Buckheit; J M Germany; J A Secrist; R Vince; W M Shannon
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

7.  Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog.

Authors:  H Soudeyns; X I Yao; Q Gao; B Belleau; J L Kraus; N Nguyen-Ba; B Spira; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction.

Authors:  E J Arts; X Li; Z Gu; L Kleiman; M A Parniak; M A Wainberg
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

9.  Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.

Authors:  Z Gu; E J Arts; M A Parniak; M A Wainberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Truncating alpha-helix E' of p66 human immunodeficiency virus reverse transcriptase modulates RNase H function and impairs DNA strand transfer.

Authors:  M Ghosh; K J Howard; C E Cameron; S J Benkovic; S H Hughes; S F Le Grice
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

View more
  18 in total

1.  Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1.

Authors:  Sebastien Wurtzer; Séverine Compain; Henri Benech; Allan J Hance; François Clavel
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 2.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.

Authors:  N Richard; H Salomon; R Rando; T Mansour; T L Bowlin; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.

Authors:  E J Arts; M E Quiñones-Mateu; J L Albright; J P Marois; C Hough; Z Gu; M A Wainberg
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1.

Authors:  Y Quan; L Rong; C Liang; M A Wainberg
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Initiation of (-) strand DNA synthesis from tRNA(3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA(3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases.

Authors:  E J Arts; S R Stetor; X Li; J W Rausch; K J Howard; B Ehresmann; T W North; B M Wöhrl; R S Goody; M A Wainberg; S F Grice
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

7.  Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.

Authors:  Z Gu; X Li; Y Quan; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms.

Authors:  Miguel E Quiñones-Mateu; Yong Gao; Sarah C Ball; Andre J Marozsan; Awet Abraha; Eric J Arts
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages.

Authors:  Edward M Kennedy; Christina Gavegnano; Laura Nguyen; Rebecca Slater; Amanda Lucas; Emilie Fromentin; Raymond F Schinazi; Baek Kim
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

10.  Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.

Authors:  Danielle Perez-Bercoff; Sébastien Wurtzer; Séverine Compain; Henri Benech; François Clavel
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.